← back to search

Daniel Vergho

University of California, Davis · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research focused on Nephrectomy and Renal cell carcinoma, with related work in Clear cell renal cell carcinoma, Inferior vena cava, Nephrology. Notable publications include 'Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy', 'Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus', and 'Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)'.
h-index
citations
488
works
16
NIH funding
primary concept
email

Recent publications

Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin
Urologia Internationalis 2024cited by 0position: middledoi
Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
Cancers 2023cited by 5position: middledoi
Evaluation of a microRNA-based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
medRxiv 2022cited by 0position: middledoi
Impact of E-Cadherin and β-Catenin as Prognostic Factor in Renal Cell Carcinoma with Tumor Thrombus of the Vena Cava
Urologia Internationalis 2019cited by 5position: lastdoi
Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients
World Journal of Urology 2017cited by 27position: middledoi
Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease
European Urology Supplements 2017cited by 0position: middledoi
Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
EJNMMI Research 2016cited by 93position: middledoi
Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival
Journal of Surgical Oncology 2016cited by 34position: middledoi
Maintenance monotherapy with Gemcitabine following cisplatin-based primary combination chemotherapy in surgically treated advanced urothelial carcinoma: A matched-pair single institution analysis
Molecular and Clinical Oncology 2016cited by 8position: middledoi
Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis
The Journal of Urology 2015cited by 41position: middledoi
Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)
Current Urology Reports 2014cited by 84position: middledoi
Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy
The Journal of Urology 2014cited by 37position: middledoi
Impact of miR-21, miR-126 and miR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
PLoS ONE 2014cited by 35position: firstdoi
Matched-pair analysis of renal function in the immediate postoperative period: a comparison of living kidney donors versus patients nephrectomized for renal cell cancer
World Journal of Urology 2014cited by 9position: firstdoi
Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus
European Urology 2013cited by 93position: middledoi
Sekundärmalignome in Harnableitungen
Der Urologe 2012cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Maximilian Burger · University of Regensburg6 papers (2014–2024)Charis Kalogirou · National Center for Tumor Diseases5 papers (2014–2023)Wolfgang Otto · University of Regensburg4 papers (2019–2024)Johannes Breyer · University of Regensburg4 papers (2019–2024)Markus Krebs · National Center for Tumor Diseases4 papers (2014–2023) · 3 papers (2014–2016)Hubert Kübler · Technical University of Munich3 papers (2019–2023) · 3 papers (2014–2023) · 3 papers (2014–2023)Ralf C. Bargou · Comprehensive Cancer Center Mainfranken2 papers (2022–2023)Philipp Spachmann · University of Regensburg2 papers (2019–2024) · 2 papers (2014–2016)Stefan Denzinger · University of Regensburg2 papers (2019–2024) · 2 papers (2022–2023) · 1 papers (2014–2014)Matthias Eiber · Comprehensive Cancer Center Erlangen1 papers (2016–2016)Matthias May · Caritas-Krankenhaus St. Josef1 papers (2014–2014) · 1 papers (2016–2016)Hans‐Juergen Wester · Technical University of Munich1 papers (2016–2016)Ken Herrmann · Indiana University – Purdue University Indianapolis1 papers (2016–2016)